Bruker Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRKR research report →
Range $50 – $80
Price Chart
About the company
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions.
- CEO
- Frank H. Laukien
- IPO
- 2000
- Employees
- 11,085
- HQ
- Billerica, MA, US
Get TickerSpark's AI analysis on BRKR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.62B
- P/E
- -52.50
- Fwd P/E
- 26.53
- PEG
- 0.45
- P/S
- 2.51
- P/B
- 3.85
- EV/EBITDA
- 84.45
- Div Yield
- 0.35%
- Gross Margin
- 47.93%
- Op Margin
- 0.01%
- Net Margin
- -3.51%
- ROE
- -5.15%
- ROIC
- 0.01%
Latest fiscal year · YoY change
- Revenue
- $3.44B+2.1%
- Gross Profit
- $1.58B-4.4%
- Op Income
- $236.00M
- Net Income
- $-8,600,000-107.6%
- EPS
- $-0.15-119.7%
- OCF Growth
- -46.6%
- FCF Growth
- -89.8%
- 52W High
- $68.98
- 52W Low
- $32.37
- 50D MA
- $59.93
- 200D MA
- $51.19
- Beta
- 1.26
- RSI (14)
- 45
- Avg Volume
- 2.34M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bruker posted modest Q3 revenue growth but delivered a much stronger-than-expected margin and EPS beat, while bookings momentum and a steadier outlook point to a better 2027 setup.· November 4, 2026
- Q3 revenue was $874 million, up 1.6% year over year, with organic revenue up 0.7%.
- Non-GAAP gross margin expanded to 51.3% and operating margin to 16.3%, while diluted non-GAAP EPS rose 24% to $0.56.
- Bookings trends improved: BSI book-to-bill stayed above 1 for the fifth straight quarter, with strength in U.S. Acad/Gov, China, and semiconductor metrology.
- Management said Q4 is now more de-risked, with full-year 2026 guidance reaffirmed for organic growth and EPS and updated only for currency.
- The company highlighted AI-linked semi metrology demand, better China and U.S. academic bookings, and new platform growth opportunities in organ-on-a-chip and diagnostics.
Bruker reported Q3 2026 revenue of $874 million, up 1.6% year over year, with organic growth of 0.7%. Non-GAAP gross margin was 51.3%, up 120 basis points, and non-GAAP operating margin was 16.3%, up 400 basis points year over year. Diluted non-GAAP EPS was $0.56, up 24.4% from $0.45 in Q3 2025. On a GAAP basis, Bruker reported a diluted loss per share of $0.81 versus a loss of $0.41 a year ago, including a non-cash goodwill impairment charge of about $175 million related to Bruker Spatial Biology. For the first nine months of 2026, revenue was $2.54 billion, up 3.1%, with organic revenue essentially flat. Management updated fiscal 2026 reported revenue guidance to $3.52 billion-$3.56 billion, implying 2.5%-3.5% growth, and said organic revenue growth should remain 1%-2% with acquisition contribution of about 1.5%. Non-GAAP operating margin is still expected to expand 250-300 basis points, and non-GAAP EPS guidance remains $2.10-$2.15. For Q4, management expects organic revenue growth in the lower mid-single digits and sequential and year-over-year improvement in operating margin and EPS.
Frank Laukien framed the quarter as evidence that Bruker’s demand recovery is broadening, with particular strength in U.S. academic/government, China, and semicon metrology. He emphasized that BSI bookings and backlog are both up mid-single digits year to date and said that should help de-risk Q4 and support acceleration into 2027 and beyond. His tone was upbeat but still cautious, repeatedly noting timing risk and quarter-to-quarter volatility, especially in academic funding and semi conversion.
Gerald Herman said Q3 came in roughly as expected on revenue but materially ahead on margins and EPS, helped by cost-saving actions and favorable mix. He cited a 120-basis-point gross margin gain to 51.3%, a 400-basis-point operating margin gain to 16.3%, and free cash flow improvement of $151 million year over year, along with $58 million of debt paydown. He said net leverage was 2.4x as of September 30, below the company’s previously communicated target, and reiterated that Bruker is on track for its $140 million annualized run-rate cost-out target.
Analysts focused on why bookings strength has not yet shown up more clearly in revenue, especially with BSI book-to-bill above 1 for five quarters. Management pointed to semi-metrology pushouts and slower-converting areas like NMR as the main reasons, while saying those orders should support Q4 and 2027 revenue conversion. Questions also centered on 2027 growth, margins, China durability, and leverage/M&A; management said 2027 should bring double-digit EPS growth, more than 100 basis points of additional margin expansion, continued China strength for now, and disciplined M&A now that leverage is below target.
The positive case from this call is that order momentum is improving across several important markets, while cost actions are translating into much better profitability. Management sounded increasingly confident that pushed-out semi orders, improving academic demand, and strong China bookings will convert into revenue in 2027, with additional support from high-margin growth areas like semicon metrology, diagnostics, and deep-tech research tools.
The main risks are timing and durability: management repeatedly noted that semi orders can slip a quarter or two, NMR and academic markets remain uneven, and China is still hard to predict beyond a few quarters. The company also took a $175 million goodwill impairment in Spatial Biology, showing that some end markets remain weak, and management still described Q4 execution as not risk-free despite the improved visibility.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.1%
- Shares Outstanding
- 152.72M
- Float Shares
- 104.05M
of shares held by institutions
435 13F filers
Buy/sell ratio 0.84. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BRKR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | May 23, 23 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Apr 17, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 10, 22 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
| Bob GibbsHouse · OH07 | Sell | Nov 27, 20 | Filing → |
| Thomas Richard CarperSenate · DE | Buy | Nov 20, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
| Bob GibbsHouse · OH07 | Buy | Nov 14, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 20.30M | ▲ 58.87K |
| Orbis Allan Gray Ltd | 17.94M | 0 |
| Blackrock, Inc. | 11.79M | ▲ 382.10K |
| Vanguard Group Inc | 10.26M | ▼ 144.44K |
| Pallas Capital Advisors LLC | 9.48M | ▼ 138 |
| Vanguard Portfolio Management LLC | 4.97M | ▲ 86.63K |
| Vanguard Capital Management LLC | 4.86M | ▲ 336 |
| State Street Corp | 4.00M | ▼ 14.77K |
| Sculptor Capital LP | 3.00M | ▼ 1.63M |
| Sachem Head Capital Management LP | 2.92M | ▲ 2.92M |
| Edmond De Rothschild Holding S.A. | 2.65M | ▼ 175.75K |
| Dimensional Fund Advisors LP | 2.58M | ▼ 32.37K |
Held by 538 ETFs
Biggest fund positions in BRKR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Munch Mark | other | 2,000 |
| Sep 15, 26 | Munch Mark | sell | 2,000 |
| Sep 15, 26 | Munch Mark | other | 2,000 |
| Aug 15, 26 | Prause Burkhard | other | 3,303 |
| Aug 15, 26 | Prause Burkhard | other | 2,678 |
| Aug 15, 26 | Pusch Wolfgang | other | 3,120 |
| Aug 17, 26 | Pusch Wolfgang | sell | 3,473 |
| Aug 15, 26 | Pusch Wolfgang | other | 2,529 |
| Aug 15, 26 | Bures Thomas | other | 4,035 |
| Aug 15, 26 | Srega Juergen | other | 16,898 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BRKR coverage
Recent articles, reports, and earnings notes.
No research on BRKR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRKR report →Here's Why Bruker (BRKR) is a Strong Momentum Stock
zacks.com · Nov 17
Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors
businesswire.com · Nov 16
Should You Continue to Retain Bruker Stock in Your Portfolio?
zacks.com · Nov 13
Bruker: Five Quarters Of Orders Are Still Waiting To Show Up In Revenue
seekingalpha.com · Nov 7
Bruker Corporation (BRKR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Bruker Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Here's What Key Metrics Tell Us About Bruker (BRKR) Q3 Earnings
zacks.com · Nov 4
Bruker (BRKR) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.